Department of Ophthalmology, Massachusetts Eye and Ear, Harvard Medical School, Boston, MA, U.S.A.
First Department of Ophthalmology, Gennimatas General Hospital, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece.
In Vivo. 2020 Jun;34(3 Suppl):1619-1628. doi: 10.21873/invivo.11952.
The novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged in China in the city of Wuhan in December of 2019 and since then more than 5,000,000 people have been infected, with approximately 338,000 deaths worldwide. The virus causes the coronavirus disease 2019 (COVID-19), which is characterized by fever, myalgia and cough, with severe acute respiratory syndrome being the most fearsome complication. Nevertheless, the vast majority of cases present mild symptoms or none. Central nervous system and cardiovascular manifestations have been reported. The range of ocular manifestations, either as a result of the infection or as a result of the treatment, has not yet been discussed. In this study, a systematic review of current literature relevant to COVID-19 was performed with focus on modes of transmission, ocular manifestations related to infection and medications, as well as the control of infection in ophthalmic practice.
新型冠状病毒，即严重急性呼吸综合征冠状病毒 2（SARS-CoV-2），于 2019 年 12 月在中国武汉市出现，此后全球已有超过 500 万人感染，约 33.8 万人死亡。该病毒引发 2019 冠状病毒病（COVID-19），其特征为发热、肌痛和咳嗽，最可怕的并发症是急性呼吸窘迫综合征。然而，绝大多数病例症状轻微或无症状。已报告有中枢神经系统和心血管系统表现。眼部表现的范围，无论是由于感染还是由于治疗，尚未讨论。在本研究中，对与 COVID-19 相关的当前文献进行了系统回顾，重点关注传播方式、与感染相关的眼部表现和药物，以及眼科实践中的感染控制。
